Compare PSEC & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PSEC | DBVT |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2014 |
| Metric | PSEC | DBVT |
|---|---|---|
| Price | $2.69 | $23.22 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $2.50 | ★ $31.75 |
| AVG Volume (30 Days) | ★ 4.1M | 186.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 20.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,151,000.00 |
| Revenue This Year | N/A | $65.50 |
| Revenue Next Year | N/A | $47.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.45 | $3.91 |
| 52 Week High | $4.36 | $26.19 |
| Indicator | PSEC | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 57.72 |
| Support Level | $2.55 | $20.23 |
| Resistance Level | $2.71 | $23.47 |
| Average True Range (ATR) | 0.09 | 1.26 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 8.75 | 83.87 |
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.